Clinical Trials
Sep 19, 2026 · 1 min read · 44,191 views
Roche says Carmot-acquired shot delivers Phase 2 win in overweight patients with diabetes
I
Isabella Hart
Editorial · Sep 19, 2026
Roche is back with more data Tuesday for the lead drug it obtained from Carmot Therapeutics - this time from a mid-stage trial in overweight or obese people with type 2 diabetes. The Swiss drugmaker's enicepatide
← Previous
Alzheon outlines plans for major fundraising round despite Phase 3 miss for Alzheimer's drug
Next →
Vertex aims for broad kidney disease label ahead of key readout next year
